AVEO Oncology Reports Full Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: RBC Capital Upgrades AVEO Pharmaceuticals (AVEO) to Sector Perform
March 9, 2015 6:50 AM EDT(Updated - March 9, 2015 8:05 AM EDT)
RBC Capital upgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Underperform to Sector Perform with a price target of $3.00 (from $2.00). Analyst Adnan Butt thinks shares could begin reflecting pipeline optionality.
"Since the setback with tivozanib in renal cancer,... More
AVEO Pharmaceuticals (AVEO) Reports FOLFOX6 Combo Phase 2 Met Intent to Treat Endpoint; Will Present Data
March 6, 2015 7:09 AM ESTAVEO Oncology (NASDAQ: AVEO) announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial, will be presented in a poster session today at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization... More
AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
March 6, 2015 6:06 AM ESTAVEO Pharmaceuticals (NASDAQ: AVEO) reported Q3 EPS of ($0.27), $0.06 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $115 thousand versus the consensus estimate of $3.25 million.
For earnings history and earnings-related data on AVEO Pharmaceuticals (AVEO) click here.
... More